Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Wednesday, Zacks reports. Cyclerion Therapeutics Trading Down 100.0% About Cyclerion Therapeutics (Get Free Report) Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the […]